Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M H Sayegh

Showing results (1-10 of 202) with videos related to

Pageof 21
Sort By:
Kidney International|November 26, 1999
Why do we reject a graft? Role of indirect allorecognition in graft rejectionM H Sayegh
The Journal of Clinical Investigation|May 4, 1999
Finally, CTLA4Ig graduates to the clinicM H Sayegh
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 1, 1996
Endothelin in organ transplantationB Watschinger, M H Sayegh
Current Opinion in Nephrology and Hypertension|May 1, 1996
Immunomodulatory function of major histocompatibility complex-derived peptidesB Murphy, M H Sayegh
Clinical and Experimental Rheumatology|November 21, 2007
The evolution of the immunobiology of co-stimulatory pathways: clinical implicationsS Trikudanathan, M H Sayegh
Expert Opinion on Investigational Drugs|November 4, 2000
CTLA4-Ig: a novel immunosuppressive agentN Najafian, M H Sayegh
Transplantation Proceedings|December 26, 2001
Achieving clinical transplant tolerance: what are the hurdles?A D Salamam, M H Sayegh
Journal of Nephrology|November 19, 1997
Current and future immunosuppressive therapies: impact on chronic allograft dysfunctionJ P Vella, M H Sayegh
Current Opinion in Immunology|November 22, 1997
Peptide-mediated immunosuppressionC C Magee, M H Sayegh
Postgraduate Medical Journal|July 1, 1997
Maintenance pharmacological immunosuppressive strategies in renal transplantationJ P Vella, M H Sayegh
Pageof 21

Showing results (1-10 of 202) with videos related to

Sort By:
Pageof 21
Kidney International|November 26, 1999
Why do we reject a graft? Role of indirect allorecognition in graft rejectionM H Sayegh
The Journal of Clinical Investigation|May 4, 1999
Finally, CTLA4Ig graduates to the clinicM H Sayegh
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 1, 1996
Endothelin in organ transplantationB Watschinger, M H Sayegh
Current Opinion in Nephrology and Hypertension|May 1, 1996
Immunomodulatory function of major histocompatibility complex-derived peptidesB Murphy, M H Sayegh
Clinical and Experimental Rheumatology|November 21, 2007
The evolution of the immunobiology of co-stimulatory pathways: clinical implicationsS Trikudanathan, M H Sayegh
Expert Opinion on Investigational Drugs|November 4, 2000
CTLA4-Ig: a novel immunosuppressive agentN Najafian, M H Sayegh
Transplantation Proceedings|December 26, 2001
Achieving clinical transplant tolerance: what are the hurdles?A D Salamam, M H Sayegh
Journal of Nephrology|November 19, 1997
Current and future immunosuppressive therapies: impact on chronic allograft dysfunctionJ P Vella, M H Sayegh
Current Opinion in Immunology|November 22, 1997
Peptide-mediated immunosuppressionC C Magee, M H Sayegh
Postgraduate Medical Journal|July 1, 1997
Maintenance pharmacological immunosuppressive strategies in renal transplantationJ P Vella, M H Sayegh
Pageof 21